Pricing and Reimbursement Policies in Estonian Pharmaceutical Market:
The case study provides an overview of the main features of the pharmaceuticals pricing andreimbursement policies in Estonia, based on a review of regulations and literature, and data analysis. The first chapter of the report provides background information on the Estonian health system context and...
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Washington, D.C
The World Bank
2018
|
| Schriftenreihe: | World Bank E-Library Archive
|
| Online-Zugang: | Volltext |
| Zusammenfassung: | The case study provides an overview of the main features of the pharmaceuticals pricing andreimbursement policies in Estonia, based on a review of regulations and literature, and data analysis. The first chapter of the report provides background information on the Estonian health system context and overall description of the pharmaceutical sector. The second chapter focuses on the pricing policies used for the retail and hospital sector medicines, while outlining the impact of current policies. The third chapter takes a closer look into the reimbursement policies for outpatient and inpatient medicines. Finally, some conclusions from the case study are provided |
| Beschreibung: | 1 Online-Ressource |
| DOI: | 10.1596/34189 |
Internformat
MARC
| LEADER | 00000nmm a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV048273447 | ||
| 003 | DE-604 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 220609s2018 |||| o||u| ||||||eng d | ||
| 024 | 7 | |a 10.1596/34189 |2 doi | |
| 035 | |a (ZDB-1-WBA)NLM01114369X | ||
| 035 | |a (OCoLC)1334021726 | ||
| 035 | |a (DE-599)GBVNLM01114369X | ||
| 040 | |a DE-604 |b ger |e rda | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-12 |a DE-521 |a DE-573 |a DE-523 |a DE-Re13 |a DE-19 |a DE-355 |a DE-703 |a DE-91 |a DE-706 |a DE-29 |a DE-M347 |a DE-473 |a DE-824 |a DE-20 |a DE-739 |a DE-1043 |a DE-863 |a DE-862 | ||
| 100 | 1 | |a Habicht, Triin |e Verfasser |4 aut | |
| 245 | 1 | 0 | |a Pricing and Reimbursement Policies in Estonian Pharmaceutical Market |c Triin Habicht |
| 264 | 1 | |a Washington, D.C |b The World Bank |c 2018 | |
| 300 | |a 1 Online-Ressource | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 490 | 0 | |a World Bank E-Library Archive | |
| 520 | |a The case study provides an overview of the main features of the pharmaceuticals pricing andreimbursement policies in Estonia, based on a review of regulations and literature, and data analysis. The first chapter of the report provides background information on the Estonian health system context and overall description of the pharmaceutical sector. The second chapter focuses on the pricing policies used for the retail and hospital sector medicines, while outlining the impact of current policies. The third chapter takes a closer look into the reimbursement policies for outpatient and inpatient medicines. Finally, some conclusions from the case study are provided | ||
| 856 | 4 | 0 | |u https://doi.org/10.1596/34189 |x Verlag |z kostenfrei |3 Volltext |
| 912 | |a ZDB-1-WBA | ||
| 943 | 1 | |a oai:aleph.bib-bvb.de:BVB01-033653642 | |
Datensatz im Suchindex
| _version_ | 1824556217925632002 |
|---|---|
| adam_text | |
| adam_txt | |
| any_adam_object | |
| any_adam_object_boolean | |
| author | Habicht, Triin |
| author_facet | Habicht, Triin |
| author_role | aut |
| author_sort | Habicht, Triin |
| author_variant | t h th |
| building | Verbundindex |
| bvnumber | BV048273447 |
| collection | ZDB-1-WBA |
| ctrlnum | (ZDB-1-WBA)NLM01114369X (OCoLC)1334021726 (DE-599)GBVNLM01114369X |
| discipline | Wirtschaftswissenschaften |
| discipline_str_mv | Wirtschaftswissenschaften |
| doi_str_mv | 10.1596/34189 |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>00000nmm a2200000zc 4500</leader><controlfield tag="001">BV048273447</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">220609s2018 |||| o||u| ||||||eng d</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1596/34189</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-1-WBA)NLM01114369X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1334021726</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)GBVNLM01114369X</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-12</subfield><subfield code="a">DE-521</subfield><subfield code="a">DE-573</subfield><subfield code="a">DE-523</subfield><subfield code="a">DE-Re13</subfield><subfield code="a">DE-19</subfield><subfield code="a">DE-355</subfield><subfield code="a">DE-703</subfield><subfield code="a">DE-91</subfield><subfield code="a">DE-706</subfield><subfield code="a">DE-29</subfield><subfield code="a">DE-M347</subfield><subfield code="a">DE-473</subfield><subfield code="a">DE-824</subfield><subfield code="a">DE-20</subfield><subfield code="a">DE-739</subfield><subfield code="a">DE-1043</subfield><subfield code="a">DE-863</subfield><subfield code="a">DE-862</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Habicht, Triin</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Pricing and Reimbursement Policies in Estonian Pharmaceutical Market</subfield><subfield code="c">Triin Habicht</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Washington, D.C</subfield><subfield code="b">The World Bank</subfield><subfield code="c">2018</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">World Bank E-Library Archive</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The case study provides an overview of the main features of the pharmaceuticals pricing andreimbursement policies in Estonia, based on a review of regulations and literature, and data analysis. The first chapter of the report provides background information on the Estonian health system context and overall description of the pharmaceutical sector. The second chapter focuses on the pricing policies used for the retail and hospital sector medicines, while outlining the impact of current policies. The third chapter takes a closer look into the reimbursement policies for outpatient and inpatient medicines. Finally, some conclusions from the case study are provided</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1596/34189</subfield><subfield code="x">Verlag</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-WBA</subfield></datafield><datafield tag="943" ind1="1" ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-033653642</subfield></datafield></record></collection> |
| id | DE-604.BV048273447 |
| illustrated | Not Illustrated |
| index_date | 2024-07-03T20:00:09Z |
| indexdate | 2025-02-20T07:20:03Z |
| institution | BVB |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-033653642 |
| oclc_num | 1334021726 |
| open_access_boolean | 1 |
| owner | DE-12 DE-521 DE-573 DE-523 DE-Re13 DE-BY-UBR DE-19 DE-BY-UBM DE-355 DE-BY-UBR DE-703 DE-91 DE-BY-TUM DE-706 DE-29 DE-M347 DE-473 DE-BY-UBG DE-824 DE-20 DE-739 DE-1043 DE-863 DE-BY-FWS DE-862 DE-BY-FWS |
| owner_facet | DE-12 DE-521 DE-573 DE-523 DE-Re13 DE-BY-UBR DE-19 DE-BY-UBM DE-355 DE-BY-UBR DE-703 DE-91 DE-BY-TUM DE-706 DE-29 DE-M347 DE-473 DE-BY-UBG DE-824 DE-20 DE-739 DE-1043 DE-863 DE-BY-FWS DE-862 DE-BY-FWS |
| physical | 1 Online-Ressource |
| psigel | ZDB-1-WBA |
| publishDate | 2018 |
| publishDateSearch | 2018 |
| publishDateSort | 2018 |
| publisher | The World Bank |
| record_format | marc |
| series2 | World Bank E-Library Archive |
| spellingShingle | Habicht, Triin Pricing and Reimbursement Policies in Estonian Pharmaceutical Market |
| title | Pricing and Reimbursement Policies in Estonian Pharmaceutical Market |
| title_auth | Pricing and Reimbursement Policies in Estonian Pharmaceutical Market |
| title_exact_search | Pricing and Reimbursement Policies in Estonian Pharmaceutical Market |
| title_exact_search_txtP | Pricing and Reimbursement Policies in Estonian Pharmaceutical Market |
| title_full | Pricing and Reimbursement Policies in Estonian Pharmaceutical Market Triin Habicht |
| title_fullStr | Pricing and Reimbursement Policies in Estonian Pharmaceutical Market Triin Habicht |
| title_full_unstemmed | Pricing and Reimbursement Policies in Estonian Pharmaceutical Market Triin Habicht |
| title_short | Pricing and Reimbursement Policies in Estonian Pharmaceutical Market |
| title_sort | pricing and reimbursement policies in estonian pharmaceutical market |
| url | https://doi.org/10.1596/34189 |
| work_keys_str_mv | AT habichttriin pricingandreimbursementpoliciesinestonianpharmaceuticalmarket |